Progression-free survival versus overall survival in ovarian cancer: where are we now?

Curr Oncol Rep. 2012 Dec;14(6):483-5. doi: 10.1007/s11912-012-0263-7.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Clinical Trials as Topic
  • Disease-Free Survival*
  • Female
  • Humans
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / pathology
  • Phthalazines / therapeutic use
  • Piperazines / therapeutic use
  • Poly(ADP-ribose) Polymerase Inhibitors*

Substances

  • Antibodies, Monoclonal, Humanized
  • Phthalazines
  • Piperazines
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Bevacizumab
  • olaparib